Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California. Show more
10880 WILSHIRE BOULEVARD, LOS ANGELES, CA, UNITED STATES, 90024, Los Angeles, CA, 90024, USA
Market Cap
397.5M
52 Wk Range
$3.03 - $8.75
Previous Close
$7.81
Open
$7.79
Volume
95,324
Day Range
$7.75 - $7.86
Enterprise Value
320.1M
Cash
36.19M
Avg Qtr Burn
N/A
Insider Ownership
15.49%
Institutional Own.
74.88%
Qtr Updated
03/31/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
NERLYNX Details Breast cancer, Cancer, ER+/HER2- breast cancer, Solid tumor/s | Approved Quarterly sales | |
NERLYNX Details Breast cancer, Sexual desire disorder, Sexual dysfunction | Approved Quarterly sales | |
Alisertib Details ER+/HER2- breast cancer, Breast cancer, Cancer | Phase 2 Update | |
Alisertib Details Cancer, Small cell lung cancer | Phase 2 Update | |
Trastuzumab Emtansine (T-DM1) With Neratinib Details Breast cancer | Phase 2 Update | |
Alisertib (2 combo trials) Details Breast cancer, ER+/HER2- breast cancer | Phase 2 Update | |
Neratinib (HKI-272) + fulvestrant + trastzuzumab Details Metastatic breast cancer, Breast cancer, Metastatic breast cancer to brain | Phase 2 Update | |
Neratinib Details Lung cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Neratinib Details Cervical cancer, Infectious disease, Catheter related blood stream infections | Phase 2 Update | |
Neratinib Details Bile duct disease, Cancer | Phase 2 Update | |
Alisertib Details Cancer, Non-small cell lung carcinoma | Phase 1/2 Update | |
Alisertib+pembrolizumab Details Head and neck squamous cell carcinoma, Cancer | Phase 1/2 Update |
